Figure 5
Efficacy of JBSNF-000028 in chronic DIO model. (A) Body weight changes (%) and cumulative energy intake in lean control animals and HFD fed animals treated with vehicle or JBSNF-000028 at 50 mg kg−1. (B) Fed blood glucose and fed plasma insulin profile of lean control animals and HFD fed animals treated with vehicle or JBSNF-000028 at 50 mg kg−1. (C) Plasma triglycerides, plasma LDL cholesterol, liver triglycerides, liver total cholesterol, MNA measurements in liver and visceral WAT samples of lean control animals and HFD fed animals treated with vehicle or JBSNF-000028 at 50 mg kg−1. (D) Oral glucose tolerance test (OGTT), (E) Area under the curve (AUC) for the OGTT. (F) Plasma insulin levels at t = 15 min. (G) Plasma insulin and (H) plasma glucose concentrations at t = 0 min. (I) HOMA-IR index. Data are presented as mean ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.0001 and ****p < 0.0001 when compared with lean Control and $p < 0.05, $$p < 0.01, $$$p < 0.001, $$$$p < 0.0001 when compared with HFD Control. Two way ANOVA followed by Bonferroni’s post-hoc test (A, B, D); One way ANOVA followed by Bonferroni’s post-hoc test (C, E–I).
